Skip to main content
Premium Trial:

Request an Annual Quote

Asked to Give DNA Back

A South African university has instructed the Wellcome Sanger Institute to return DNA samples it has that were collected from indigenous African communities, The Times reports.

According to The Times, officials from Stellenbosch University say the Sanger sought to commercialize samples that had been provided to it to study "population history and human evolution." Researchers from African universities and the Lebanese American University collected these samples from indigenous populations, including the Nama people, solely for research and not for commercialization, it adds.

But in a letter sent to the Sanger, the Stellenbosch officials say they learned the Sanger was in talks with Thermo Fisher to develop a commercial research tool based on these samples and that this "raises serious legal and ethical consequences," as The Times reports.

The Sanger denies the allegations and says it did not breach its agreement, according to The Times. It adds that the Sanger says that a person working at the institute proposed the commercialization work, but that the institute did not pursue it.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.